In vitro and in vivo activity of a new small-molecule inhibitor of HDAC6 in mantle cell lymphoma.

Cancer origin and development is associated not only with genetic alterations, but also with the disturbance of epigenetic profiles.[1][1] In this regard, the tumoral epigenome is characterized by both specific and general shifts in the DNA methylation and histone-modification landscapes.[1][1]